Gouty Arthritis Market Report 2026

Gouty Arthritis Market Overview

• Gouty Arthritis market size has reached to $3.69 billion in 2025 • Expected to grow to $5.06 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: The Impact Of Obesity On The Gouty Arthritis Market • Market Trend: Innovative Options In Gouty Arthritis Treatment • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Gouty Arthritis Market?

Gouty arthritis is a type of inflammatory arthritis characterized by sudden, severe attacks of pain, redness, and swelling in the joints, often the big toe. It is caused by the accumulation of uric acid crystals within the joint, leading to intense inflammation and discomfort. Gout can be managed with medications and lifestyle changes to reduce uric acid levels and prevent future flare-ups. The main types of gouty arthritis include acute gouty arthritis and chronic gouty arthritis. Acute gouty arthritis is a type of arthritis that happens suddenly and causes intense pain, swelling, and redness in the joints, often affecting the big toe. The treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), pain relievers, corticosteroids, xanthine oxidase inhibitors, uricosurics, and others for diagnosis such as joint fluid test, blood test, X-ray imaging, ultrasound, dual-energy computed tomography (CT) scan, and others. The distribution channels include hospital pharmacies, retail pharmacies, and others for end-users such as hospitals, specialty clinics, and others.

What Is The Gouty Arthritis Market Growth Forecast?

The gouty arthritis market size is expected to see strong growth in the next few years. It will grow to $5.06 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to aging population growth, chronic disease awareness, preventive arthritis care, improved patient compliance, personalized gout treatment approaches. Major trends in the forecast period include increasing prevalence of hyperuricemia, rising demand for long-term disease management, growth of combination drug therapies, improved diagnostic imaging adoption, expansion of lifestyle-based disease management.

Global Gouty Arthritis Market Segmentation

1) By Type: Acute Gouty Arthritis, Chronic Gouty Arthritis 2) By Treatment: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Pain Reliever, Corticosteroids, Xanthine Oxidase Inhibitors, Uricosurics, Other Treatments 3) By Diagnosis: Joint Fluid Test, Blood Test, X-Ray Imaging, Ultrasound, Dual Energy Computed Tomography (CT) Scan, Other Diagnosis 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels 5) By End-Users: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Acute Gouty Arthritis: Monosodium Urate Crystals-Induced Acute Gout, Acute Gout Attack (Intermittent Flares), Severe Acute Gout With Joint Deformities 2) By Chronic Gouty Arthritis: Tophaceous Gout (Presence Of Uric Acid Deposits), Chronic Gout With Joint Damage, Chronic Gout With Renal Complications, Chronic Gout With Comorbidities (Hypertension, Diabetes)

What Is The Driver Of The Gouty Arthritis Market?

The increasing prevalence of obesity is expected to propel the growth of the gouty arthritis market going forward. Obesity is a medical disorder characterized by the buildup of extra body fat to the point where it threatens an individual's health and is frequently measured using the body mass index (BMI). The rate of obesity is rising due to increased consumption of high-calorie, processed foods and sedentary lifestyles. Obesity contributes to gouty arthritis by increasing the production of uric acid and reducing the body's ability to excrete it, leading to the accumulation of uric acid crystals in the joints. Additionally, excess body weight places more stress on joints, exacerbating the inflammation and pain associated with gout. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, from 2023 to 2024, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity, up from 64.0% in 2022 to 2023. Therefore, the increasing prevalence of obesity is driving the growth of the gouty arthritis industry.

Key Players In The Global Gouty Arthritis Market

Major companies operating in the gouty arthritis market are Horizon Therapeutics plc, Pfizer Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bayer AG, Bristol Myers Squibb, Novartis International AG, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, GlaxoSmithKline plc, Teijin Pharma Ltd, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, JW Pharmaceutical, Arthrosi Therapeutics Ltd, XORTX Therapeutics Inc, Atom Therapeutics Co Ltd, Olatec Therapeutics LLC, InventisBio Co Ltd, Shanton Pharma, Selecta Biosciences Inc, LG Chem Ltd, Protalix BioTherapeutics Inc

Global Gouty Arthritis Market Trends and Insights

Major companies operating in the gouty arthritis market are increasing their efforts to develop novel products, such as cortrophin gel, to provide more effective and targeted therapies for managing the condition. Cortrophin gel, also known as repository corticotropin injection, is a purified form of the adrenocorticotropic hormone (ACTH). It is used to treat various inflammatory and autoimmune conditions, including gouty arthritis. For instance, in October 2023, ANI Pharmaceuticals, a US-based pharmaceutical company, received approval from the Food and Drug Administration for a new 1-mL vial size of Purified Cortrophin Gel. This product is intended for the adjunctive treatment of certain patients experiencing acute gouty arthritis flares. Cortrophin Gel is currently the only FDA-approved adrenocorticotropic hormone (ACTH) therapy indicated for treating appropriate patients with acute gouty arthritis flares.

What Are Latest Mergers And Acquisitions In The Gouty Arthritis Market?

In October 2023, Amgen Inc, a US-based biotechnology company, acquired Horizon Therapeutics plc for an $27.8 billion. With this acquisition, Amgen aimed to strengthen and expand its rare-disease and inflammation drug portfolio, thereby broadening its therapeutic reach and accelerating revenue and growth potential. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company that specializes in provides treatments for gouty arthritis

Regional Outlook

North America was the largest region in the gouty arthritis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gouty Arthritis Market?

The gouty arthritis market consists of revenues earned by entities by providing services such as diagnostic testing, physical therapy, pain management programs, and dietary counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The gouty arthritis market also includes sales of ibuprofen, naproxen, topical pain relievers, and ice packs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gouty Arthritis Market Report 2026?

The gouty arthritis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gouty arthritis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.